Tensioline 120 gélules
Food supplement declared in France, declaration No 2019-10-695
Tensioline 120 gélules (LTLABORATOIRE) is a food supplement declared in France. Status: withdrawn from the market on 30 June 2024. Main ingredients: Hieracium pilosella 600 mg per day, Olea europaea 450 mg per day, Allium sativum 150 mg per day, Psidium guajava 8.1 mg per day, Ocimum tenuiflorum 2.7 mg per day. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- LTLABORATOIRE
- Food business operator placing the product on the market
- LUBERON TECHNOLOGIES LABO (LT LABO ORGANOSILICES.LT LABO ELIXIRS) (LTLO LTELF LTLSVN)
- Status
- Withdrawn from the market on 30 June 2024
- Form
- Capsule
- Daily dose
- 3
- Directions for use
- 2 à 3 gélules par jour, avec un verre d’eau.
- Not recommended (according to the manufacturer)
- Pregnant women, Taking anticoagulants, Prolonged use
- Objectives stated by the manufacturer (these are not authorised claims)
- Blood and lymphatic circulation
Declaration 215173, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Hieracium pilosella L. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 600 mg |
| Olea europaea subsp. europaea | Feuille | Extrait sec aqueux | 450 mg |
| Allium sativum L. | Bulbe | Extrait sec hydroalcoolique | 150 mg |
| Psidium guajava L. | Fruit | Extrait sec aqueux | 8.1 mg |
| Ocimum tenuiflorum L. | Feuille | Extrait sec aqueux | 2.7 mg |
| Citrus limon (L.) Burm. f. | Fruit | Extrait sec aqueux | 2.7 mg |
Other ingredients
Extrait de riz, Gélule végétale
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Ne peut remplacer une alimentation variée et équilibrée et un mode de vie sain. Tenir hors de portée des jeunes enfants. Ne pas dépasser la dose journalière recommandée. Déconseillé aux personnes sous traitement anticoagulant. Utilisation prolongée déconseillée sans avis médical. Déconseillé chez la femme enceinte. Conserver à l'abri de la chaleur dans un endroit sec.
Regulatory points
- Conditions légales
Psidium guajava L.: Seule l'utilisation des extraits aqueux et alcooliques de titre faible (25% v/v) est autorisée
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Information
Withdrawn from the market on 30 June 2024, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Olea europaea subsp. europaea
Read the warning, when it applies and the studies cited
OLIVE LEAF - OLEA EUROPAEA
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Known adverse reactions
Condition of application: All products except those making a diuretic claim.
When using this product diuretic effect may occur.
- Allium sativum L.
Read the warning, when it applies and the studies cited
Garlic - Allium sativum
Route of administration: Oral
Cautions and warnings
Condition of application: Relief of upper respiratory tract infections and catarrhal (nasal congestion) conditions.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or protease inhibitors (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Ocimum tenuiflorum L.
Read the warning, when it applies and the studies cited
HOLY BASIL - OCIMUM TENUIFLORUM - SEED
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular condition (Rai et al. 1997; Agrawal et al. 1996).
Sources cited by Health Canada (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).
Sources cited by Health Canada (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed
Condition of application: Relief of cough; Digestive aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 February 2026
HOLY BASIL - OCIMUM TENUIFLORUM - LEAF
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (WHO 2002).
Sources cited by Health Canada (2)
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a heart condition or diabetes (Rai et al. 1997; Agrawal et al. 1996).
Sources cited by Health Canada (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).
Sources cited by Health Canada (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed
Condition of application: Relief of cough/cold/respiratory mucus buildup; Digestive aid; Adaptogen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant (Prakash et al. 2005; Ahmed et al. 2002; WHO 2002; Wohlmuth 2002; Kapoor 2001).
Sources cited by Health Canada (6)
- Ahmed A, Ahamed RN, Aladakatti RH, Ghoseawar MG. Reversible antifertility effect of benzene extract of Ocimum sanctum on sperm parameters and fructose content in rats. Journal of basic and clinical physiology and pharmacology 2002;13:51-59. PubMed
- Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
- Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian Journal of Physiology and Pharmacology 2005;49(2):125-131. PubMed Review article
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
- Wohlmuth H. Sacred basil - an Ayurvedic adaptogen. Botanical Pathways, 2002; Issue 11.
- OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : LTLABORATOIRE
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Tensioline 120 gélules (LTLABORATOIRE): composition and regulation”, https://compoatlas.com/en/supplements/products/215173-tensioline-120-gelules, updated 15 November 2026.